News
News | CAS Experts Visit Wanbangde Pharmaceutical for Discussions and Exchange to Drive Product Enhancements
Date:
17 May,2024
Recently, Ye Yang, Secretary of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences; Professor Liu Jia, researcher at the institute; Professor Zhu Mulan from the Chenshan Science Center of the Center for Excellence in Molecular Plant Sciences, CAS; and Dr. Chen Yang and consultant Teacher Jin from Shanghai Jin Yangguang Biotechnology visited Wanbangde Pharmaceutical Group to jointly discuss matters related to enhancing the company’s core products—huperzine A and Ginkgo Leaf Dropping Pills.
Secretary Ye Yang and his delegation, accompanied by Zhao Shouming, Chairman of the Group, and Zhuang Hui, Vice Chairman, paid a site visit to the Group’s pharmaceutical exhibition hall, where they learned about the company’s product R&D initiatives and its strategic focus on key product development. Over the years, Wanbangde Pharmaceutical Group has been dedicated to the research, development, and production of huperzine A and Ginkgo biloba droplets, while actively advancing the integration of industry, academia, and research. The company is also committed to cultivating specialized, niche, and highly focused pharmaceutical solutions, with a particular emphasis on building a comprehensive, end-to-end industrial chain for its flagship products—huperzine A and Ginkgo biloba droplets.
At the symposium, Chairman Zhao Shouming delivered the opening remarks, warmly welcoming all the experts to attend and expressing his sincere hope for further optimization and enhancement of the shishan alkaloid and ginkgo leaf varieties. The attending experts, highly optimistic about the company’s potential for variety development and improvement, shared their insights and offered thoughtful ideas and suggestions aimed at refining and elevating the company’s product lines.
The successful convening of this seminar has clearly pointed the way toward enhancing the company’s R&D and manufacturing capabilities for its core product lines. Wanbangde Pharmaceutical Group will further strengthen collaboration with leading experts, solidify its integrated industry chain, and deliver high-quality medicines to patients—fully upholding the social responsibility that pharmaceutical companies should embrace. Moreover, the group is committed to showcasing and advancing the groundbreaking scientific achievements of globally innovative products.
Related Recommendations